Sec Form 4 Filing - Longitude Venture Partners L.P. @ CORCEPT THERAPEUTICS INC - 2014-05-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Longitude Venture Partners L.P. 2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 800 EL CAMINO REAL, SUITE 220 3. Date of Earliest Transaction (MM/DD/YY) 05/01/2014 (Street) MENLO PARK, CA94025 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/01/2014 S 160,343 D $ 4.1245 ( 1 ) 12,595,325 ( 2 ) D ( 3 ) Common Stock 05/01/2014 S 3,214 D $ 4.1245 ( 1 ) 174,691 ( 4 ) D ( 5 ) Common Stock 05/02/2014 S 84,744 D $ 4.0718 ( 6 ) 12,510,581 ( 2 ) D ( 3 ) Common Stock 05/02/2014 S 1,699 D $ 4.0718 ( 6 ) 172,992 ( 4 ) D ( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Deriv ative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Longitude Venture Partners L.P. 800 EL CAMINO REAL SUITE 220 MENLO PARK, CA94025 X X Longitude Capital Associates, L.P. 800 EL CAMINO REAL SUITE 220 MENLO PARK, CA94025 X Longitude Capital Partners, LLC 800 EL CAMINO REAL SUITE 220 MENLO PARK, CA94025 X Tammenoms Bakker Juliet LONGITUDE CAPITAL MANAGEMENT CO., LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA94025 X Signatures /s/ Juliet Tammenoms Bakker, as managing member of Longitude Capital Partners, LLC, as general partner of Longitude Venture Partners, L.P. 05/05/2014 Signature of Reporting Person Date /s/ Juliet Tammenoms Bakker, as managing member of Longitude Capital Partners, LLC, as general partner of Longitude Capital Associates, L.P. 05/05/2014 Signature of Reporting Person Date /s/ Juliet Tammenoms Bakker, as managing member 05/05/2014 Signature of Reporting Person Date /s/ Juliet Tammenoms Bakker 05/05/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reflects sales of common stock executed in multiple transactions at prices ranging from $4.0700 to $4.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. ( 2 )Does not include warrants held by Longitude Venture Partners, L.P. ("LVP") to purchase 3,091,479 shares of common stock. ( 3 )Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital") and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein. ( 4 )Does not include warrants held by Longitude Capital Associates, L.P. ("LCA") to purchase 26,583 shares of common stock. ( 5 )Reflects transactions and holdings of shares of common stock held of record by LCA. This report is jointly filed by LCA, Longitude Capital and Juliet Tammenoms Bakker, all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Tammenoms Bakker disclaims beneficial ownership of these securities except to the extent of their respective pecuniary interest therein. ( 6 )Reflects sales of common stock executed in multiple transactions at prices ranging from $4.0000 to $4.1100. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.

Remarks: ***All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan***

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.